Health Library · Turkey, Quality & Local Manufacturing

How Technology Transfer Improves Quality in Local CAR-T Manufacturing

Educational article · Updated 2026

When people hear “local manufacturing” of an advanced therapy, a common concern is quality. Will a product made closer to home meet the same standards as one produced in a long-established facility in the United States, Europe or another experienced region?

The answer depends heavily on how local manufacturing is set up. One of the strongest ways to protect quality is technology transfer of an already-developed and approved product, rather than building a completely new therapy from early research stages.

This article explains what technology transfer means for CAR-T, which elements are transferred, and why this model can support high manufacturing standards in a new location.

What technology transfer means in CAR-T

Technology transfer is the structured process of moving a manufacturing method, analytical methods, quality standards and operational know-how from one organization (the originator) to another (the receiving laboratory).

In the context of CAR-T, it typically includes:

• The detailed manufacturing process (cell activation, gene transfer, expansion, formulation)
• Specifications for starting materials and critical reagents
• Analytical methods used for in-process control and final release testing
• Acceptance criteria (what “pass” looks like for identity, potency, purity and safety tests)
• Training of personnel and documentation systems
• Experience with process variability and troubleshooting

The goal is not to invent a new product. The goal is to reproduce an existing, characterized product under controlled local conditions so that patients can receive something that is comparable to the original.

Why starting from an approved product matters

There is an important difference between two approaches:

• Early-stage domestic development — a laboratory designs its own CAR construct, develops a process, and begins clinical trials. This is valuable for long-term scientific capacity, but the product still has to prove itself step by step. Clinical efficacy and safety data are still being generated.
• Technology transfer of an already-approved product — the receiving site works with a product that has already undergone clinical evaluation and regulatory review in its origin country. Published data on response rates, durability and side effects already exist. Manufacturing and quality methods have already been refined through real production experience.

In the second model, local production is built on a foundation that already includes clinical evidence and process maturity. This does not eliminate the need for local validation, training and regulatory oversight, but it starts from a much higher baseline than a brand-new research program.

What this means for quality expectations

In a properly executed technology-transfer setting, several quality-supporting elements are present from the outset:

• An origin product that has already undergone regulatory review and has published clinical safety and efficacy data
• A defined manufacturing process that has been operated at commercial or late-clinical scale in the origin country
• Established analytical methods and release specifications that the receiving site is trained to perform
• The requirement to validate the process locally under GMP and to demonstrate that local batches meet the predefined quality attributes

These elements do not make any manufacturing site automatically perfect. They do, however, provide a structured foundation that is substantially different from an early research program that is still defining its process and generating its first patient data.

For patients and referring physicians, the practical value of this model is transparency: the origin clinical results can be examined, the intended manufacturing and quality standards can be discussed, and the treating center’s experience with cellular therapy can be evaluated directly.

How quality is protected during transfer

Quality does not automatically travel with the paperwork. A successful transfer requires deliberate work in several areas:

1. Process understanding and documentation

The receiving laboratory obtains detailed process descriptions, batch records, control strategies and knowledge of critical process parameters. Operators are trained not only on the steps, but on why those steps matter and how to respond when results are near limits.

2. Analytical methods and release testing

CAR-T release testing is multi-layered. Typical elements include:

• Cell identity and CAR expression (usually by flow cytometry)
• Viability and cell number
• Vector copy number (genetic dose)
• Functional potency (for example antigen-specific cytokine release)
• Confirmation of intended genetic or functional features (such as checkpoint knockdown when part of the design)
• Safety tests: sterility, mycoplasma, endotoxin, residual impurities, and strategies related to replication-competent virus risk

Transferring the methods and the acceptance criteria helps ensure that the local laboratory is measuring the same quality attributes with the same expectations as the originator.

3. Comparability and validation

Regulators and quality systems expect evidence that the product made at the new site is comparable to the product made at the original site. This involves process validation runs, side-by-side analytical work where appropriate, and demonstration that the local process consistently meets predefined specifications.

4. Quality culture and oversight

Written procedures are necessary but not sufficient. Ongoing quality management, deviation handling, change control, environmental monitoring and regular training are what keep a manufacturing operation reliable over time.

What technology transfer does not remove

Even with a strong transfer, several responsibilities remain fully local:

• Day-to-day execution of manufacturing under GMP
• In-process monitoring and real-time decision making
• Final release decisions according to the approved specifications
• Coordination with the clinical center for collection and infusion timing
• Compliance with national regulatory requirements

Technology transfer reduces the need to rediscover the entire science of the product. It does not remove the obligation to run a disciplined manufacturing and quality operation.

Why this model can improve access without lowering standards

Local manufacturing of a transferred product can offer practical advantages while preserving quality expectations:

• Shorter and more controlled logistics — living cells travel shorter distances, which can reduce risk and complexity.
• Potentially shorter vein-to-vein time — once the process is stable, proximity can help with scheduling and turnaround.
• Cost structure — local production can avoid some of the overhead associated with long-distance commercial supply chains, which may support more accessible pricing.
• Continuity with clinical evidence — physicians and patients can refer to the published data of the origin product rather than waiting for an entirely new evidence package.

None of these advantages replace the need for rigorous quality systems. They become meaningful only when the manufacturing and release standards remain high.

How patients and physicians can evaluate a technology-transfer pathway

Useful questions include:

• Is the local product based on a construct and process that already has regulatory approval and published clinical results in another jurisdiction?
• What quality-control and release tests are performed before infusion?
• Is manufacturing conducted under GMP conditions with appropriate oversight?
• What clinical center will manage collection, infusion and toxicity management?
• How is comparability between the origin and local product addressed?

These questions apply in any country. Geography is secondary to the quality of the process, the evidence base of the product, and the experience of the treating team.

Bottom line

Technology transfer is one of the most effective ways to establish local CAR-T manufacturing while protecting quality. By starting from an already-developed product, transferring process knowledge, analytical methods and release standards, and validating the process at the new site, a laboratory can aim for consistency with the origin product rather than inventing quality from zero.

For patients, the practical implication is that “local” does not have to mean “experimental from the ground up.” When transfer is done properly, local production can combine the clinical evidence of an approved product with the operational advantages of manufacturing closer to the patient.